Medtronic Q2 FY26: Revenue $9.0B (+5.5% organic), non-GAAP EPS $1.36 (+8%); raises FY26 guidance

Medtronic plc

2026-Q2 EPS reported $1.87 revenue$17,539,000,000

Q2 organic revenue growth 5.5% (beat guidance midpoint by 75 bps); GAAP EPS $1.07 (+8%), non-GAAP EPS $1.36 (+8%).
Cardiovascular revenue $3.44B (+9.3% organic); Cardiac Ablation Solutions up 71% on PFA portfolio.
Raises FY26 organic revenue growth guidance to ~5.5% (from ~5.0%); non-GAAP EPS guidance to $5.62-$5.66.
Received FDA approval for Altaviva device for urge UI; CMS NCD for Symplicity hypertension procedure.
Diabetes revenue $757M (+7.1% organic); Hugo robotic surgery study met safety and effectiveness endpoints.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.